Compare
uniQure N.V. vs Pyxis Oncology, Inc. vs CV Sciences, Inc. vs Tonix Pharmaceuticals Holding Corp.
| Latest fiscal year | uniQure N.V. QURE | Pyxis Oncology, Inc. PYXS | CV Sciences, Inc. CVSI | Tonix Pharmaceuticals Holding Corp. TNXP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $16.10M | $13.86M | $13.79M | $13.11M |
| Revenue growth (YoY) | -40.6% | -14.2% | -12.2% | +29.8% |
| Gross margin | 89.5% (computed) | 82.8% (computed) | 49.0% | 49.3% (computed) |
| Operating margin | n/m | -609.2% | -3.4% | -959.1% |
| Net margin | n/m | -574.5% | -6.9% | -946.2% |
| Net income | -$198.97M | -$79.62M | -$958.0K | -$124.02M |
| EPS (Diluted) | -$3.46 | -$1.28 | -$0.01 | -$14.57 |
| Operating cash flow | -$177.96M | -$63.50M | -$407.0K | -$99.84M |
| Free cash flow | -$178.40M | -$63.51M | -$516.0K | -$103.21M |
| Cash & equivalents | $80.24M | $15.42M | n/a | $207.64M |
| Total assets | $824.91M | $91.52M | $6.96M | $277.17M |
| Total liabilities | $626.01M | $38.11M | $5.49M | $32.02M |
| Shareholders' equity | $198.90M | $53.41M | $1.47M | $245.15M |
| Return on year-end equity | -100.0% | -149.1% | -65.3% | -50.6% |
| Shares outstanding | 62.34M | 62.69M | 184.26M | 12.79M |
Revenue, most recent five fiscal years
| Fiscal year | uniQure N.V. | Pyxis Oncology, Inc. | CV Sciences, Inc. | Tonix Pharmaceuticals Holding Corp. |
|---|---|---|---|---|
| Latest | $16.10M Ended 2025-12-31 | $13.86M Ended 2025-12-31 | $13.79M Ended 2025-12-31 | $13.11M Ended 2025-12-31 |
| 1 year earlier | $27.12M Ended 2024-12-31 | $16.15M Ended 2024-12-31 | $15.71M Ended 2024-12-31 | $10.09M Ended 2024-12-31 |
| 2 years earlier | $15.84M Ended 2023-12-31 | n/a | $16.00M Ended 2023-12-31 | $7.77M Ended 2023-12-31 |
| 3 years earlier | $106.48M Ended 2022-12-31 | n/a | $16.20M Ended 2022-12-31 | n/a |
| 4 years earlier | $524.00M Ended 2021-12-31 | n/a | $20.05M Ended 2021-12-31 | n/a |